<DOC>
	<DOCNO>NCT00688519</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy U0267 subject plaque-type psoriasis .</brief_summary>
	<brief_title>Study Compare U0267 Against Vehicle Subjects With Plaque-type Psoriasis One Two Phase 3 Studies</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female subject least 12 year old good general health . Mild moderate plaquetype psoriasis Known allergy adverse reaction calcipotriene vitamin D analog ; component investigational formulation History hypercalcemia vitamin D toxicity . Diagnosis generalize pustular erythrodermic exfoliative psoriasis . Other serious skin disorder chronic medical condition well control . Use nonbiologic systemic antipsoriatic therapy biologic therapy within four week enrollment . Use topical therapy know beneficial effect psoriasis , within 2 week enrollment . Systemic medication medical condition know affect psoriasis within past four week enrollment . Use investigational therapy within 4 week enrollment . Pregnant woman , woman breast feeding , sexually active woman child bear potential practicing acceptable method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Plaque-type Psoriasis</keyword>
	<keyword>Psoriasis</keyword>
</DOC>